Dendritic Cells and CCR7 Expression: An Important Factor for Autoimmune Diseases, Chronic Inflammation, and Cancer

Abstract

Chemotactic cytokines—chemokines—control immune cell migration in the process of initiation and resolution of inflammatory conditions as part of the body’s defense system. Many chemokines also participate in pathological processes leading up to and exacerbating the inflammatory state characterizing chronic inflammatory diseases. In this review, we discuss the role of dendritic cells (DCs) and the central chemokine receptor CCR7 in the initiation and sustainment of selected chronic inflammatory diseases: multiple sclerosis (MS), rheumatoid arthritis (RA), and psoriasis. We revisit the binary role that CCR7 plays in combatting and progressing cancer, and we discuss how CCR7 and DCs can be harnessed for the treatment of cancer. To provide the necessary background, we review the differential roles of the natural ligands of CCR7, CCL19, and CCL21 and how they direct the mobilization of activated DCs to lymphoid organs and control the formation of associated lymphoid tissues (ALTs). We provide an overview of DC subsets and, briefly, elaborate on the different T-cell effector types generated upon DC–T cell priming. In the conclusion, we promote CCR7 as a possible target of future drugs with an antagonistic effect to reduce inflammation in chronic inflammatory diseases and an agonistic effect for boosting the reactivation of the immune system against cancer in cell-based and/or immune checkpoint inhibitor (ICI)-based anti-cancer therapy.

Single-cell transcriptomics reveals cell type–specific immune regulation associated with anti-NMDA receptor encephalitis in humans

“…Our data showed a dysregulation in the balance of myeloid populations in anti-NMDARE patients, as manifested by a substantial increase in monocyte subsets and DC_CCR7. The central chemokine receptor CCR7 plays a role in T-cell activation, differentiation, and expansion of IgG-producing B cells ( 68 ). Blocking CCR7 signaling seems to reduce both humoral and immune cell-mediated pathogenic courses, making CCR7 a potential target for interference with anti-NMDARE.…”

Substance P promotes immunotherapy efficacy for airway allergy

“… 34 Chemokine receptor CCR7 in DCs is associated with the pathogenesis of chronic inflammation, autoimmune diseases, and cancer. 35 Our data show that the gene activities of CCR7 are higher in DCs of AAD mice. The significance of this event needs to be further investigated.…”

Presentation of the levels of Gene Expression of Titanium Dioxide Nanoparticles in Caco-2/HT29-MTX, SAE, and THP-1 cells, using Bioinformatics tools (in silico)

“…The receptor, identified as a gene induced by the Epstein-Barr virus (EBV), is considered a mediator of the effects of this virus on B lymphocytes; it is expressed in various lymphoid tissues and activates B and T lymphocytes; controls the migration of memory T cells to inflamed tissues, as well as stimulates the maturation of dendritic cells (REFSEQ, 2014) 7 . Brandum et al (2021) present a review where they discuss the role of dendritic cells (DCs) and the central chemokine receptor CCR7 in the initiation and maintenance of chronic inflammatory diseases, such as multiple sclerosis (MS), rheumatoid arthritis (RA), and psoriasis. The researchers conclude that the CCR7 gene is a possible target for future drugs that can reduce inflammation in chronic inflammatory diseases and boost the reactivation of the immune system against cancer.…”